Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 5Recruiting 4Active not recruiting 3Terminated 2Enrolling by invitation 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 363Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Leukemia 61Neoplasms, Plasma Cell 60Lymphoma 59Recurrence 52Neoplasms 34Vomiting 33Lymphoma, Non-Hodgkin 32Immunoglobulin Light-chain Amyloidosis 27Lymphoma, Mantle-Cell 26Burkitt Lymphoma 26Nausea 22Lymphoma, Large B-Cell, Diffuse 21Leukemia, Lymphocytic, Chronic, B-Cell 21Waldenstrom Macroglobulinemia 19Prostatic Neoplasms 19Lymphoma, Follicular 18Hodgkin Disease 18Neoplasm Metastasis 14Breast Neoplasms 14Amyloidosis 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Acute 11Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 9Lymphoma, Large-Cell, Immunoblastic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Cutaneous 8Colonic Neoplasms 8

Interventions

Lenalidomide 7Dexamethasone 5Calcium Dobesilate 4elotuzumab 2Denosumab 2siltuximab 1piperine 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Urination 1Receptors, Interleukin-6 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Nivolumab 1Melphalan 1Maintenance 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1Immunotherapy, Active 1IPH-2101 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Cytogenetic Analysis 1Cyclophosphamide 1Curcumin 1Celecoxib 1BHQ880 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Smoldering Multiple Myeloma × Dexamethasone × Clear all
NCT02916771 2025-08-11

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
61 enrolled 12 charts
Plasma cell

Smoldering Multiple Myeloma

NCT02903381 2023-06-13

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
8 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

NCT02279394 2023-06-09

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
51 enrolled 14 charts
Plasma cell

Smoldering Multiple Myeloma

NCT02492750 2020-03-25

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

Mayo Clinic

Phase 1 Completed
14 enrolled 12 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT00480363 2013-07-31

QUIREDEX

PETHEMA Foundation

Phase 3 Completed
120 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡